OncoMatch/Clinical Trials/NCT04969731
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Is NCT04969731 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Immuncell-LC and Gemcitabine for pancreatic ductal adenocarcinoma.
Treatment: Immuncell-LC · Gemcitabine — PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgery — curative intent (R0 or R1 resection)
Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resection based on the baseline, up to 12 weeks.
Cannot have received: anticancer therapy
Exception: Neo-adjuvant therapy for pancreatic cancer is allowed
Received anticancer therapy including chemotherapy, biological therapy, immunotherapy, hormone therapy, radiation therapy, and other anti-cancer treatments. Note: Neo-adjuvant therapy for pancreatic cancer is allowed.
Cannot have received: Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs
Received Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs within three years prior to screening.
Lab requirements
Blood counts
Absolute neutrophil count 3E= 1,500/b5L; Hemoglobin level 3E= 9 g/dL; Platelet count 3E= 100,000/b5L
Kidney function
BUN, serum creatinine 3C= 1.5 d7 institutional upper limit of normal (ULN)
Liver function
AST, ALT 3C= 2.5 d7 institutional upper limit of normal (ULN)
Adequate organ and marrow function at the screening and baseline as defined below: Absolute neutrophil count 3E= 1,500/b5L; Hemoglobin level 3E= 9 g/dL; Platelet count 3E= 100,000/b5L; BUN, serum creatinine 3C= 1.5 d7 institutional upper limit of normal (ULN); AST, ALT 3C= 2.5 d7 institutional upper limit of normal (ULN); PT (INR), activated partial thromboplastin time (aPTT) 3C= 1.5 d7 institutional upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04969731 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages